POLE and non-small cell lung carcinoma: Further, in NSCLC patients treated with anti-PD-1 blockade, responders with the highest mutational burden contained mutations in POLD1, POLE, and MSH2, and nonsynonymous mutational burden and neo-antigen load in these patients correlated with enhanced clinical response [8].